摘要
乳腺癌是女性常见的恶性肿瘤,目前治疗方法采用以手术为主的综合治疗方案,并强调个体化。雌激素受体(ER)与人类表皮生长因子受体2(HER-2)是影响乳腺癌预后的2个非常重要的生物学指标,两者并不同时在乳腺癌组织中表达。
出处
《中国临床医生杂志》
2011年第7期9-11,共3页
Chinese Journal For Clinicians
参考文献10
-
1Schlag PM, Benhidje B. Hyperthermic radiochemotherapy for e- sophageal cancer rationale and conception of phase In trim [ J ]. Onkologie, 1999,22 (91 ) : 48 - 55.
-
2Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination : influence of hormonal status and HER-2 in breast cancer a study from the IMPACT trialists [ J]. ClinOnco1,2005,23 ( 11 ) : 2477 - 2492.
-
3Rakha EA, E1-Sayed ME, Green A. Prognostic marker intriple- negative breast cancer[ J]. Cancer,2007,109 ( 1 ) : 25 - 29.
-
4Torrisi R,Balduzzi A,Ghisini R,et al. Tailored preoperative treat- ment of locally advanced triple negative( hormone receptor negative and HER2 negative) breast cancer with epirubicin, eieplatin, and infusional fluorouracil followed by weekly paclitaxel [ J ]. Cancer Chemother Pharmaeol, 2008,62 ( 4 ) : 667 - 669.
-
5Gradishar WJ, Tjutandin S, Davidson N, et al. Phase 3 Trial of nanoparticle albumin-bound compared with polyethylated castor oil-based paclitaxel in women with breast cancer [ J ]. Clin On- col ,2005,23 (31) : 7794 -7803.
-
6Gholam D, Chebib A, Hanteville D, et al. Combined paclitaxel and cetuximab achieved a major, response on the skinmetastases of a patient with epidermal growth factor receptor-positive, estro- gen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast Cancer[ J ]. Anticancer Drugs,2007,18 ( 7 ) : 835 - 838.
-
7Bria E,Nistico C,Cuppone F,et al. Benefit of taxanes as adju- vant chemotherapy for early breast cancer: pooled analysis of 15 500 patients [ J ]. Cancer, 2006,106 ( 11 ) : 2337 - 2344.
-
8Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treat- ment of early breast cancer[ J ]. Cochrane Database of Systematic Reviews 2007, (4) : 475 - 478.
-
9Sparano J, Wang M, Martino S, et al. Weekly paclitaxel in the ad- juvant treatment of breast cancer [ J 3. N Engl J Med, 2008,358 ( 16): 1663 - 1671.
-
10Quill T, Abair T, Garcia K, et al. The american society of clinical oncology 2009 breast cancer symposium [ J ]. Clin Breast Canc- er,2009,9 (4) : 213 - 218.
同被引文献38
-
1Beata B, Joanna N. Prognostic potential of topoisomerase IIa and HER-2 in a retrospective analysis of early advanced breast caneer patients treated with adjuvant anthracycline chemotherapy[ J ]. Breast,2011,3 : 1-13.
-
2Van Dongen JA, Voogd AC, Fentinan IS, et al. Long-term results of a randomized trial comparing breast conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer [ J ]. Trial, 2000,92 ( 14 ) : 1143- 1150.
-
3Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009[J]. Annals of Oncology , 2009,20(8) :1319-1329.
-
4胡夕春,王碧芸.转移性乳腺癌内科治疗进展[J].中国临床肿瘤学进展,2010,8:281-283.
-
5Voravud N, Phase II trial of ramosetron plus dexamethaso- nein the prevention of cisplatin-induced nausea and vomiting [ J]. MedAssoc Thai ,2005, 88 (12) : 1790-1796.
-
6Larrey D, Pageaux GP. Drug-induced acute liver failure [ J ]. Eur J Gastroenterol Hepatol,2005,17 : 141-143.
-
7Kosmas C, Kallistratos M, Kopterides P, et al. Cardiotoxici- ty of fluoropyrinidines in different schedules of administra- tion: a prospective study[ J ]. J Cancer Res Clin Oncol,2008, 134 : 75-82.
-
8徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27(24):1913-1916. 被引量:20
-
9Balslev I, Axelsson C K, Zedeler K, et al. The Notting- ham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) [J~, Breast Cancer Res Treat, 1994, 32 (3) :281-290.
-
10Burness M L, Grushko T A, Olopade O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a mark- er~J]. Cancer J, 2010, 16(1 ) :23-32.
引证文献4
-
1曹华,闫茂生,王树滨,许瑞莲,陈亦欣,郑涛.三阴性与非三阴性乳腺癌的临床分析[J].中国临床医生杂志,2013,41(8):50-52. 被引量:11
-
2刘亚慧,赵庆春,孟威宏.乳腺癌术后复发转移患者药学监护1例[J].药物流行病学杂志,2014,23(8):505-508.
-
3刘光旭,任圣楠,房学东,何燕.乳腺癌表皮生长因子受体与Bcl-2的表达及其临床意义[J].武警医学,2015,26(4):383-386. 被引量:5
-
4邢智伟.恶性肿瘤基础与高等化疗方案的个体化选择[J].临床医药文献电子杂志,2016,3(56):11085-11085.
二级引证文献16
-
1赵宗兴,杨建征,张亚男.乳腺癌术后大分割放疗研究进展[J].中国临床医生杂志,2014,42(5):24-25. 被引量:11
-
2周国庆,郑冬梅,杜靖,兰涛,蔡建辉.亚甲蓝示踪不同部位乳腺癌前哨淋巴结转移规律的临床观察[J].中国临床医生杂志,2014,42(5):67-69. 被引量:3
-
3李慧芳,姚艳敏,刘景萍,胡健,郑薇薇,赵亚婷.超声下乳腺癌图像特点与腋淋巴结转移的相关因素分析[J].中国临床医生杂志,2014,42(6):63-65. 被引量:14
-
4符娇文,韩平,符贵超.半夏泻心汤对胃癌前病变大鼠胃黏膜中B细胞淋巴瘤-2与表皮生长因子受体表达影响[J].四川中医,2018,36(12):50-53. 被引量:21
-
5曹华,郑涛,许瑞莲,陈亦欣,闫茂生.CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2在三阴性乳腺癌中表达的研究[J].中国临床医生杂志,2014,42(8):32-35. 被引量:1
-
6赵丽丽,张春生,吴红卫.异时性双侧原发三阴乳腺癌一例报告并文献复习[J].解放军医药杂志,2015,27(3):114-116. 被引量:1
-
7姜文婧,任斐.放疗在乳腺癌中的应用发展及不良反应[J].中国药物与临床,2015,15(6):810-812. 被引量:2
-
8赵康康,赵宗兴,任晓俊,刘倩,厉超,杨建征.以腋窝肿大淋巴结为首发症状的男性隐性乳腺癌[J].中国临床医生杂志,2015,43(8):90-92.
-
9王丽,杨帆,孔祥顺,刘运江,刘登湘.uPA、PAI-1组织表达与新辅助化疗治疗乳腺癌疗效及预后的相关性分析[J].解放军医药杂志,2016,28(6):33-35. 被引量:4
-
10王承伟,许刚,薛辉,张良.乳腺癌改良根治术后不同放疗技术的剂量学比较及不良反应观察[J].甘肃医药,2016,35(12):881-884. 被引量:7
-
1宋泉毅,张大昕.微RNA与肺癌及人类表皮生长因子受体突变状态的研究进展[J].医学综述,2016,22(4):703-706. 被引量:2
-
2邓明凤,王昌富,郭华雄,陈登峰,黄俊,李滔.乳腺癌患者HER2基因表达状态及临床病理意义探讨[J].中国实验诊断学,2011,15(2):330-332.
-
3杨顺娥,李迅.雌激素受体β和人类表皮生长因子受体2在乳腺癌中的表达及其临床意义[J].中华肿瘤杂志,2007,29(10):767-768. 被引量:6
-
4周桂台.三阴乳腺癌的临床特点及预后分析[J].中国当代医药,2010,17(31):157-157.
-
5舒文斌,曹家庆.HER-2在胃癌研究中的新进展[J].生命科学,2013,25(3):324-328. 被引量:3
-
6王春燕,汤丽娜,祁伟祥,张剑军,郑水儿,姚阳,林峰.HER-2过表达与骨肉瘤预后关系的Meta分析[J].山东医药,2015,55(8):70-72.
-
7任泽华,张一清,李金峰.乳腺浸润性小叶癌与浸润性导管癌比较分析[J].中国药物与临床,2012,12(8):1075-1077. 被引量:5
-
8李森,李治国,成龙,薛英威.H er -2阳性胃癌靶向治疗的研究进展[J].实用肿瘤学杂志,2015,29(2):188-192. 被引量:7
-
9王传省,张芳.三阴性乳腺癌96例临床特征与预后分析[J].肿瘤研究与临床,2013,25(5):350-352. 被引量:10
-
10乔建兵,陈文萍.酪氨酸激酶抑制剂耐药机制及其治疗策略[J].中国肺癌杂志,2011,14(10):806-810. 被引量:4